Liraglutide Helped Patients Still Obese After Bariatric Surgery Lose Significantly More Weight | Research

The takeaway

Patients who remained obese 6 months after bariatric surgery lost more than twice as much weight with 12 weeks of liraglutide (1.8mg) compared to controls, with additional improvements in fatty liver and blood pressure.

11.6% vs 4.9% TWL
Total weight loss in liraglutide vs control groups at 24 weeks post-treatment initiation

What the researchers found

Twelve weeks of liraglutide (1.8mg) in post-bariatric patients with persistent obesity produced 11.6% total weight loss versus 4.9% in controls, with an estimated treatment difference of 6.6% and improved metabolic outcomes.

Why it matters

Bariatric surgery doesn't work equally for everyone, and some patients need additional help losing weight. This study provides evidence that adding liraglutide relatively early after surgery can significantly boost weight loss results, potentially preventing the long-term health consequences of persistent obesity.

The numbers in context

61 patients with BMI ≥28.0 kg/m² at 6 months postoperatively. Liraglutide 1.8 mg used.

How the study worked

Retrospective cohort study of 61 patients with BMI ≥28 kg/m² at 6 months post-metabolic surgery. 27 received liraglutide 1.8mg for 12 weeks; 34 were controls. Primary endpoint: change in %TWL at 24 weeks.

Who was studied

Patients with BMI ≥28 at 6 months post-bariatric surgery

What this study cannot tell us

Retrospective design limits causal conclusions. Small sample size (n=61) with unequal groups. Used the lower 1.8mg dose (the weight-management dose is 3.0mg). Short treatment period (12 weeks) with 24-week follow-up. Single-center study.

How to read the evidence

Moderate evidence from a retrospective cohort study with a meaningful sample size and clear outcomes, though limited by non-randomized design and small cohort.

When this study was published

Published in 2024. Addresses the growing clinical question of combining GLP-1 drugs with bariatric surgery.

The bigger picture

The combination of bariatric surgery and GLP-1 drugs is an emerging strategy for patients with severe obesity. As more potent GLP-1 agonists become available (semaglutide, tirzepatide), the question of when and how to add pharmacotherapy after surgery becomes increasingly relevant for clinical practice.

Questions still open

Would higher doses of liraglutide (3.0mg) or semaglutide produce even greater weight loss in this population?
What is the optimal timing to start GLP-1 therapy after bariatric surgery?
Do the weight loss benefits persist after discontinuing liraglutide in post-surgical patients?

Common questions

Why would someone still be obese after bariatric surgery?

Bariatric surgery success varies based on factors like procedure type, starting weight, metabolism, eating habits, and genetics. Some patients don't lose enough weight or regain weight after surgery. Having a BMI still ≥28 at 6 months post-surgery suggests insufficient initial response.

Is it safe to take GLP-1 drugs after bariatric surgery?

In this study, no serious adverse events were reported with liraglutide after surgery. However, patients should work closely with their medical team, as GLP-1 drugs affect appetite and gut function, which are already altered by surgery.

Read the original research

The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(12), 2499-2513

View on PubMed ↗Publisher’s paper ↗

Citation

Shen, Yuanyuan; Huang, Yuanhao; Ouyang, Yuqin; Xiang, Xinyue; Chu, Xuehui; Zhang, Bingqing; Han, Tao; Tang, Wenjuan; Feng, Wenhuan. (2024). The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(12), 2499-2513. https://doi.org/10.1007/s13300-024-01643-1